| abstract |
1,3,5-trisubstituted indazole derivatives of the formula <IMAGE> (I) wherein R1 is H, (b) a C1-6 straight or branched, substituted or unsubstituted alkyl residue, (c) a C3-7 cycloalkyl residue, (d) an unsustituted or substituted phenyl, naphthyl, anthranyl, or fluorenyl residue, (e) a quinolin-2-ylmethoxy, or pyridin-2-ylmethoxy residue; X is O, or a -NH, -NH-(C=O)-NH-, -NH-(C=O)-O-, -NH-(C=O)-, or -NH-CH2-(C=O)- residue; Y is O, or S; R2 is H; Z is a SO, SO2, -(CH2)p-, -(CH2)p-O-, -O-(CH2)p-, -(CH2)p-(C=O)-, -(C=O)-(CH2)p-, -(CH2)p-(C=O)-NH-, -NH-(C=O)-(CH2)p-, -(CH2)p-CHOH-, -CHOH-(CH2)p-, -(CH2)p-CH=CH-, or -CH=CH-(CH2)p- residue, wherein p is between 1 and 6; A is a phenyl, naphthyl, anthranyl, fluorenyl, thiophenyl, pyridinyl, isoxazolyl, benzimidazolyl, benz[1,3]dioxolyl, pyrimidyl, pyrimidine-2,4-dionyl, quinolinyl, quinoxazolinyl, morpholinyl, or pyrrolidinyl residue; and, R3, R4, and R5, the same or different, are defined in the specification; and pharmaceutically acceptable salts, stereoisomers, racemates, racemic modifications, and enantiomers thereof. The invention also relates to specific compounds, processes for preparing and for treating an allergic, asthmatic, inflamed condition of a host, or for modulating the immune system of a host. |